Advancing Adaptive Strategies for Clinical Trial Supply Manufacturing

·        Strategies for just-in-time manufacturing to reduce inventory and waste

·        CMO Selection: Aligning Partner Capabilities with Evolving Clinical Supply Demands

·        Modernizing the Supply Chain: Evaluating and Adopting Next-Generation Manufacturing Solutions

Localising clinical trial supply in (J)APAC: Risk, resilience, and revenue

With JAPAC now the fastest-growing clinical trial region, sponsors need local supply strategies to de-risk programs and improve patient access. This session explains the necessity of building resilient, compliant local supply networks and the commercial upside for manufacturers and CROs across and within JAPAC

  • Why JAPAC matters now: JAPAC trial activity is accelerating vs. other regions, major growth in China and parts of Asia(https://www.reuters.com/business/healthcare-pharmaceuticals/china-pharma-firms-turn-local-reagent-s…)
  • Supply risk: reliance on Europe/US creates delays and vulnerability: Local sourcing reduces lead times and tariff risk (recent moves to local reagents/manufacturing)(Reuters)
  • Practical actions: rapid tech-enabled cold chain, local comparator sourcing, in-region labelling/regulatory templates and contract manufacturing partnerships

Building Resilient Clinical Supply Chains: From Seamless Comparator Sourcing, Labeling, Packaging to Last-Leg Delivery in Global Clinical Trials

This session, will provide an insightful overview of how Jupiter Research Services’ bespoke service model enables Sponsors, CROs, and CDMOs to leverage a truly global and resilient clinical supply chain – encompassing Seamless Comparator Sourcing, Regulatory-Compliant Labeling & Packaging, and Efficient Last-Leg Delivery across multi-regional clinical trials

  • Identifying, Mapping & Mitigating Risks in a Volatile Supply Chain
    – Understanding how global shortages, parallel trade shifts, customs complexities, and cold-chain vulnerabilities impact study timelines—and how to proactively mitigate them.
  • Resilient & “Glocal” Comparator Sourcing Strategies
    – Approaches that combine global reach with local execution to reduce bottlenecks, prevent study interruptions, and secure critical US/EU comparator products for global trials.
  • Overcoming Regulatory Challenges for Uninterrupted Study Operations
    – Navigating FDA, EMA, MHRA, MFDS, PMDA, CDSCO, DSCSA/EPCIS, and QP release requirements to maintain continuity and compliance across regions.
  • Integrated Labeling, Packaging & Blinding for OTD (On-Time Delivery)
    – A coordinated, risk-based approach to labeling, packaging, kitting, and blinding that ensures accuracy, compliance, version control, and timely delivery.
  • Application of JIT, DTP & Innovative Supply Models
    – Deploying Just-in-Time (JIT) packaging, Direct-to-Patient (DTP) distribution, and flexible logistics models that support decentralized and hybrid trials.
  • Case Studies: Successful End-to-End Execution
    – Real-world examples demonstrating rapid comparator procurement, seamless global-to-local execution, proactive QA oversight, and uninterrupted delivery to sites and patients.